GEP-NETs
This marks the first FDA approval of a radioactive drug for patients 12 years or older with SSTER-positive GEP-NETs.
Researchers also found statistical significance for the TBR SULpeak of the primary and liver lesions.
Dr. Christopher Lieu gives an overview of the BESPOKE trial and the GALAXY arm of CIRCULATE-Japan, as well as NETTER-2.
PREF-NET was the first study to investigate patients’ preference of LAN administration setting in England and Wales.
For patients with NETs, somatostatin receptors are often targeted for nuclear theranostics applications.
Investigators compared the benefits of a nomogram with the AJCC staging system in predicting overall survival.
Advertisement
Expert Interviews on GI Oncology
Advertisement
